RGEN has 36-month beta value of 0.95. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RGEN is 52.09M, and currently, short sellers hold a 7.53% ratio of that float. The average trading volume of RGEN on September 27, 2024 was 847.42K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RGEN) stock’s latest price update
Repligen Corp. (NASDAQ: RGEN)’s stock price has plunge by 5.43relation to previous closing price of 139.60. Nevertheless, the company has seen a 0.96% surge in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-24 that WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center (“RTIC”) at its Waltham headquarters.
RGEN’s Market Performance
RGEN’s stock has risen by 0.96% in the past week, with a monthly rise of 0.79% and a quarterly rise of 16.27%. The volatility ratio for the week is 3.92% while the volatility levels for the last 30 days are 3.87% for Repligen Corp. The simple moving average for the past 20 days is 2.49% for RGEN’s stock, with a -10.48% simple moving average for the past 200 days.
Analysts’ Opinion of RGEN
Many brokerage firms have already submitted their reports for RGEN stocks, with Wells Fargo repeating the rating for RGEN by listing it as a “Overweight.” The predicted price for RGEN in the upcoming period, according to Wells Fargo is $180 based on the research report published on August 28, 2024 of the current year 2024.
Deutsche Bank, on the other hand, stated in their research note that they expect to see RGEN reach a price target of $155, previously predicting the price at $180. The rating they have provided for RGEN stocks is “Buy” according to the report published on June 26th, 2024.
RGEN Trading at -0.28% from the 50-Day Moving Average
After a stumble in the market that brought RGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.29% of loss for the given period.
Volatility was left at 3.87%, however, over the last 30 days, the volatility rate increased by 3.92%, as shares surge +1.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.24% upper at present.
During the last 5 trading sessions, RGEN rose by +0.96%, which changed the moving average for the period of 200-days by -7.59% in comparison to the 20-day moving average, which settled at $143.70. In addition, Repligen Corp. saw -18.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RGEN starting from Hunt Anthony, who sale 22,191 shares at the price of $145.37 back on Sep 10 ’24. After this action, Hunt Anthony now owns 139,840 shares of Repligen Corp., valued at $3,225,927 using the latest closing price.
Hunt Anthony, the Officer of Repligen Corp., proposed sale 22,191 shares at $144.72 during a trade that took place back on Sep 10 ’24, which means that Hunt Anthony is holding shares at $3,211,481 based on the most recent closing price.
Stock Fundamentals for RGEN
Current profitability levels for the company are sitting at:
- 0.02 for the present operating margin
- 0.41 for the gross margin
The net margin for Repligen Corp. stands at -0.0. The total capital return value is set at 0.0. Equity return is now at value -0.10, with -0.07 for asset returns.
Based on Repligen Corp. (RGEN), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.3. The interest coverage ratio of the stock is 1.28.
Currently, EBITDA for the company is 131.39 million with net debt to EBITDA at -2.52. When we switch over and look at the enterprise to sales, we see a ratio of 13.57. The receivables turnover for the company is 4.89for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.65.
Conclusion
To put it simply, Repligen Corp. (RGEN) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
